(Total Views: 306)
Posted On: 06/14/2019 10:58:04 AM
Post# of 154868
In my opinion, most investors hoped that the amount of cash raised would be enough to get Leronlimab to market for HIV combo WITHOUT any further dilution. It’s hard to imagine that $12 million will meet that goal, but we’ll have to wait and see what the prostate licensing deal brings in and other any other licensing deal that may present itself.
Additionally, CYDY may have hoped that a good TO would assist the company in going the combo route alone. $40 million from the TO and cash from the prostate licensing deal could potentially make that happen, but it seems unlikely with only $12 million raised.
The $12 million, plus any current cash, will hopefully get CYDY through BLA milestones, prostate test licensing and possibly TNBC interim results so that the next TO or dilution is at a higher evaluation.
Additionally, CYDY may have hoped that a good TO would assist the company in going the combo route alone. $40 million from the TO and cash from the prostate licensing deal could potentially make that happen, but it seems unlikely with only $12 million raised.
The $12 million, plus any current cash, will hopefully get CYDY through BLA milestones, prostate test licensing and possibly TNBC interim results so that the next TO or dilution is at a higher evaluation.
(0)
(0)
